Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC) ...